You are here: Industry Insights > Tesaro

News List

FDA approves GSK’s Jemperli for endometrial cancer pharmaceutical-technology
April 26, 2021
The US Food and Drug Administration (FDA) has approved GlaxoSmithKline’s (GSK) programmed death receptor-1 (PD-1) blocking antibody Jemperli (dostarlimab-gxly) based on its Biologics License Application (BLA) for endometrial cancer.
GSK closes $5.1bn Tesaro acquisition pharmaceutical-technology
January 24, 2019
GlaxoSmithKline (GSK) has completed its acquisition of US-based biopharmaceutical company Tesaro for an aggregate cash consideration of $5.1bn....
GlaxoSmithKline Extends Tender Offer for TESARO, Inc. firstwordpharma
January 16, 2019
The completion of the tender offer is conditioned upon the tender by TESARO stockholders of at least one Share more than 50% of the issued and outstanding Shares.
With Tesaro in the bag, GSK's cancer pipeline is pumping again fiercepharma
January 10, 2019
When she put cancer back on the front burner last year, GlaxoSmithKline CEO Emma Walmsley gave the company a big task. After all, her predecessor had traded away most of GSK's oncology assets to Novartis.
Tesaro's deal struggles? They're actually a good omen for Clovis: analyst fiercepharma
December 20, 2018
PARP drugmaker Tesaro may have had a tough time finding a buyer in GlaxoSmithKline. But that doesn’t mean rival Clovis won’t be able to land its own, one analyst says.
Tesaro's deal struggles? They're actually a good omen for Clovis: analyst fiercepharma
December 20, 2018
PARP drugmaker Tesaro may have had a tough time finding a buyer in GlaxoSmithKline. But that doesn’t mean rival Clovis won’t be able to land its own, one analyst says.
Thorny path: A replay of how Tesaro got its $5.1B GlaxoSmithKline buyout fiercepharma
December 18, 2018
With its Tesaro buyout, GlaxoSmithKline CEO Emma Walmsley finally beefed up in oncology, one of the fields she tagged for growth about a year ago. For the small biotech, the sale marked the end of a longer and more arduous journey.
GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company worldpharmanews
December 07, 2018
The proposed transaction will significantly strengthen GSK's pharmaceutical business, accelerating the build of GSK's pipeline and commercial capability in oncology.
GSK to acquire cancer therapeutics firm Tesaro for $5.1bn pharmaceutical-technology
December 05, 2018
GlaxoSmithKline (GSK) has signed a merger agreement to buy US-based biopharmaceutical company Tesaro for an aggregate consideration of around $5.1bn in a cash-based transaction......
GSK adds to cancer offering with $5.1bn Tesaro buy pharmatimes
December 04, 2018
GlaxoSmithKline is buying US oncology biopharma Tesaro for $5.1 billion, marking the first major purchase by the firm since chief executive Emma Walmsley took charge last year.

Previous page 1 2 3 Next page